Skip to main content
  • English
  • Français
  • Español
  • Russian
  • Portuguese
  • Polish

Breadcrumb

  1. Home
  2. Gynecology
  3. Breast cancer, antibiotics and gut microbiota: a losing combination
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographic
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
Dermatology

Breadcrumb

  1. Home
  2. Gynecology
  3. Breast cancer, antibiotics and gut microbiota: a losing combination
Gynecology

Breast cancer, antibiotics and gut microbiota: a losing combination

Cancer
Gynecology Gastroenterology Oncology

Antibiotics are commonly used among breast cancer patients, to prevent opportunistic infections for instance, or during periods of immunodeficiency. The researchers in this study show, in a mouse model of breast cancer, that antibiotics may accelerate tumor growth by inducing imbalances in the gut microbiota.

Gastroenterology
Gynecology
Pediatrics
Dermatology
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographic
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • Mail

About this article

Created 31 December 2021
Updated 03 March 2022

The gut microbiota has been linked to disease progression in several cancers. However, there is limited research detailing its influence in breast cancer. At the same time, antibiotics have an impact on the bacterial population of the gut microbiota. Antibiotic use is common among cancer patients, despite controversy surrounding the benefits. Accordingly, a study evaluating the effect of antibiotics on the gut microbiota and their impact on the clinical course of breast cancer was overdue. A recent study in a mouse model published in iSciences has filled the gap.

Accelerated tumor growth and microbiota depletion in mice receiving antibiotic treatment

Both before and after injection with breast cancer-specific tumor cells, mice were given a cocktail of antibiotics: vancomycin, neomycin, metronidazole, amphotericin, and ampicillin (VNMAA). Compared to the control group, these animals rapidly exhibited significantly accelerated tumor growth and strong depletion of the gut microbiota.

The researchers then focused on the effects of an antibiotic widely used in breast cancer patients: cephalexin. Although cephalexin had a smaller impact on the microbiota than the VNMAA cocktail, it caused a similar increase in tumor growth.

Anti-tumor role of certain gut bacteria

In the mice undergoing antibiotic treatment, metagenomics revealed a dysbiosis which, while not favorable to pathogenic bacteria, adversely affected protective bacteria. Animals treated with VNMAA and cephalexin had a lower relative abundance of bacteria thought to play an anti-tumor role: Lactobacillus reuteri, Lachnospiraceae bacterium, and Faecalibculum rodentium. By simply reintroducing the latter bacteria, the previous level of tumor growth was restored.

Mast cells, drivers of tumor growth in dysbiosis

Antibiotic-induced microbiota disturbances do not have a significant impact on the tumor immune microenvironment. However, they do increase the number of mast cells in the tumor stroma.

The researchers treated both control and VNMAA-treated mice with cromolyn, a mast cell stabilizer. While cromolyn inhibited tumor growth in the antibiotic-treated mice, it had no effect on the controls. These data suggest a potential role for mast cells in breast cancer progression in individuals with antibiotic-induced dysbiosis.

Even though this study was performed on a mouse model, it opens up new perspectives for the treatment of breast cancer. It is now necessary to identify what causes the increase in mast cells, what changes occur in mast cells as a result of microbiota disruption, what causes these changes, and how it causes them.

Sources

McKee AM, Kirkup BM, Madgwick M, et al. Antibiotic-induced disturbances of the gut microbiota result in accelerated breast tumor growth. iScience. 2021 Aug 20;24(9):103012.

Tags
Mast cells Breast cancer Dysbiosis Antibiotic

en_view en_sources

    See also

    Actu PRO : Cancer du sein : l’efficacité de l’immunothérapie déterminée par le microbiote intestinal ? Breast cancer: efficacy of immunotherapy conditioned by the gut microbiota?
    Created 31 December 2021
    Updated 03 March 2022

    About this article

    To know more about this topic.

    Main topic

    Cancer

    Medical practice

    Gynecology Gastroenterology Oncology

    Content type

    News

    Continue reading

    News
    Photo: Neonatal sepsis: the microbiota pays a heavy price for antibiotic use
    09.05.2022

    Neonatal sepsis: the microbiota pays a heavy price for antibiotic use

    Read the article
    04.05.2022

    Miscarriage: Is vaginal dysbiosis a suspect?

    Read the article
    26.04.2022

    Severe obesity: the vicious circle of biotin metabolism

    Read the article
    22.04.2022

    SCFAs: new intestinal markers of Parkinson’s disease?

    Read the article

    New perspectives in autism: the role of microbiota in social communication

    Overview By Dr. Vincent Trebossen Child and Adolescent P...

    Find out more

    Vaginal microbiota #15

    By Pr. Markku Voutilainen Turku University Faculty of Medicine; Turku University Hospital, Department of Ga...

    Find out more

    Infographics to share with your patients!

    Download original graphic material to explain to your patients the role of the microbiota in their daily he...

    Find out more
    15.04.2022

    Multiple sclerosis and microbiota: does meat consumption play a role?

    Read the article
    What's worth reading about microbiota
    Follow us on Twitter
    Read our thematic folder
    The Janus face of Antibiotics: Life Savers & Microbiota Disrupters
    NL13_cover
    Check out latest newsletter
    IBS, Microbiota & Covid-19
    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology
    • English
    • Français
    • Español
    • Russian
    • Portuguese
    • Polish

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

    Lay public section

    Find here your dedicated section

    en_redirection

    en_you_are_about_to_leave

    • en_be_redirected
    • en_stay_on_biocodex

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive once a month the “Microbiota Digest” to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    Photo: Neonatal sepsis: the microbiota pays a heavy price for antibiotic use
    09.05.2022

    Neonatal sepsis: the microbiota pays a heavy price for antibiotic use

    Read the article
    04.05.2022

    Miscarriage: Is vaginal dysbiosis a suspect?

    Read the article
    26.04.2022

    Severe obesity: the vicious circle of biotin metabolism

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive once a month the “Microbiota Digest” to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

    © 2022 Biocodex. All rights reserved.

    • Cookies Policy
    • Data protection policy
    • GTU
    • Sitemap
    • Cookies settings
    Biocodex logo